Latest News About Nevanac Eye Drop

Nevanac is an nepafenac eye drop used to reduce postoperative inflammation and pain after cataract surgery and, in some cases, to lower the risk of macular edema in diabetic patients after cataract surgery. Here’s what’s relevant right now based on official product information and regulatory summaries.

• Latest regulatory and clinical notes: The most recent official summaries describe Nevanac as a prescription eye drop with a profile of potential corneal adverse events (e.g., punctate keratitis, corneal epithelial defects) and the need to discontinue if corneal health worsens; these signals have been present in European and US labeling and post-marketing experience [EMC SmPC and EMA EPAR documents]. This means clinicians monitor corneal integrity during treatment and adjust therapy as needed.[1][2][3]

• Typical usage schedule: Nevanac is administered as a suspension containing nepafenac. The dosing depends on the strength: 1 mg/mL typically three times daily (with treatment beginning before surgery and continuing for 2–3 weeks postoperatively for inflammation control) or 3 mg/mL once daily for certain indications; exact regimens should follow the product labeling and a clinician’s prescription [EMA EPAR, EMA product information].[2][3]

• Safety and warnings: Common adverse reactions include local eye effects such as punctate keratitis; serious but rarer events include corneal epithelial defects and other ocular surface issues. Patients with a history of NSAID sensitivity or ocular surface disease should use with caution, and those with signs of corneal breakdown should discontinue and seek ophthalmic evaluation.[3][1]

• Availability and updates: Nevanac remains a prescription-only product in regions covered by EMA labeling, with updates issued as new post-marketing data emerge. If you’re evaluating current availability or recent safety communications, checking the latest SmPC (UK/EU) and regulatory summaries is advisable.[1][2][3]

If you’d like, I can pull the most up-to-date patient-facing summaries (e.g., patient information leaflet) or extract a quick at-a-glance checklist for monitoring eye health while using Nevanac, and I can also search for any country-specific recent updates (UK, EU, US) and summarize them. Just tell me which region you’re interested in.

Citations:

• Nevanac SmPC and safety signals.[1]
• EMA EPAR and product information overview.[2][3]